- Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial
- In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). The annual decline in eGFR slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the period following the last rilparencel injection. This 4.6 mL/min/1.73m2 per year difference was statistically significant (p
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
On 6ix: 6ix.com/news/prokidney-reports-statistically-and-clinically-significant-topline-results-phase-2
In the deck
Story so far
- ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
- ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
- ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
Earlier from ProKidney
- ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
- ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
- ProKidney Reports Full Year 2024 Financial Results and Business Highlights
- ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
Later from ProKidney
- ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
- ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
- ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
- ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
- ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
Follow ProKidney into a list and get an email when it puts out news.
Follow ProKidney